Re: Re: Revlimid too costly in the UK

[Guest guest]

Refusal by Insurance companies for use of Revlimid is already an established fact -

Re: Revlimid too costly in the UK

I'm not sure if it's a pereception problem (not accounting for expenses to test this and other new drugs for approved and new indications) ... but the very high cost of revlimid has been cited (off the record) by patients and professionals alike as approaching, if not achieving, gouging status. A collegue with myeloma relating the cost exceeds 40K per year, which seems very high -- assuming also that manufacturing costs are not as high as for biologics). Since revlimid is a one-of-a-kind drug, there's no competition to help keep costs down at this time. I'm contemplating writing a letter to the company as a patient representative to ask for an explanation for the market price of this drug. I would not be surprised to see insurance carriers in US deny reimubursement for reasonable off-label us of it as well, based on the cost. Karl

>

> Telegraph.co.uk by , Medial Editor Oct. > 28,2008 "Thousands of Cancer Patients Could Be Denied a New Drug"

> > http://www.telegraph.co.uk/news/newstopics/politics/health/3269747/Thous

> ands-of-cancer-patients-could-be-denied-a-new-drug.html

> > Marilyn Barbera

>

------------------------------------